Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel L Jacoby

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Circulation|June 24, 2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With PioglitazoneLawrence H Young, Catherine M Viscoli, Gregory G Schwartz, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 30, 2021
Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretationAndrea D Thompson, Adam S Helms, Anamika Kannan, et al.
The American Journal of Cardiology|April 19, 2026
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract GradientsJosef Veselka, Ramon Gimeno, Theodore P Abraham, et al.
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
JACC. Heart Failure|April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyAhmad Masri, Martin S Maron, Theodore P Abraham, et al.
JCI Insight|June 14, 2019
Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradationRonald Ng, Heather Manring, Nikolaos Papoutsidakis, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Circulation|June 24, 2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With PioglitazoneLawrence H Young, Catherine M Viscoli, Gregory G Schwartz, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 30, 2021
Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretationAndrea D Thompson, Adam S Helms, Anamika Kannan, et al.
The American Journal of Cardiology|April 19, 2026
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract GradientsJosef Veselka, Ramon Gimeno, Theodore P Abraham, et al.
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
JACC. Heart Failure|April 26, 2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyAhmad Masri, Martin S Maron, Theodore P Abraham, et al.
JCI Insight|June 14, 2019
Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradationRonald Ng, Heather Manring, Nikolaos Papoutsidakis, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
Pageof 6